Starling Oncology, Inc. (STLN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Starling Oncology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services
Prev close 6.37 · gapped above the open, then crossed back over prior close. High/low 6.55 at 6:00 am ET, 6.33 at 3:30 pm ET.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for Starling Oncology, Inc. yet.
120 managers report a position worth $233.3M between them, and 20 of them hold 80% of it.
each tick is a filing
STLN (Starling Oncology, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.